LRRK2 G2019S variant is associated with transcriptional changes in Parkinson’s disease human myeloid cells under proinflammatory environment

Abstract excerpt

The G2019S mutation in the leucine-rich repeat kinase 2 (LRRK2) gene is a major risk factor for the development of Parkinson's disease (PD). LRRK2, although ubiquitously expressed, is highly abundant in cells of the innate immune system. Given the importance of central and peripheral immune cells in the development of PD, we sought to investigate the consequences of the G2019S mutation on microglial and monocyte...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Neuroinflammation and Neurodegeneration Mechanisms
• Share to Parkinson's Disease Mechanisms and Treatments
• Share to RNA regulation and disease